Janssen-Cilag Manufacturing LLC (manufacturing of unpackaged product, primary and secondary packaging)

The drug is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older, and adults up to 65 years of age.

Dosage form: tablets, extended-release

ATC: N06BA04